DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tarka (Trandolapril / Verapamil Hydrochloride Extended Release) - Summary



  • When pregnancy is detected, discontinue TARKA as soon as possible.
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (see WARNINGS: Fetal Toxicity).


TARKA® (trandolapril/verapamil hydrochloride ER) combines a slow release formulation of a calcium channel blocker, verapamil hydrochloride, and an immediate release formulation of an angiotensin converting enzyme inhibitor, trandolapril.

TARKA is indicated for the treatment of hypertension.

This fixed combination drug is not indicated for the initial therapy of hypertension (DOSAGE and ADMINISTRATION).

In using TARKA, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see WARNINGS: Neutropenia/Agranulocytosis).
See all Tarka indications & dosage >>


Media Articles Related to Tarka (Trandolapril / Verapamil)

Targeted Therapies May Ease Severe Pulmonary Hypertension
Source: Medscape Critical Care Headlines [2015.09.29]
A new analysis has spotted a mortality reduction in patients with severe pulmonary hypertension caused by lung disease, but doubts remain.
Medscape Medical News

Targeting hypertension by helping pharmacists deliver enhanced patient care
Source: Hypertension News From Medical News Today [2015.09.21]
Patients with high blood pressure are benefiting from the expanded role played by pharmacists in Alberta, according to a new study from the University of Alberta's Faculty of Medicine & Dentistry.

Hypertension drug reduces inflammation from traumatic brain injury
Source: Hypertension News From Medical News Today [2015.09.21]
A new study on the processes causing inflammation after a TBI identifies a protein produced in the liver that can be blocked using a drug for hypertension.

New imaging technique reveals early brain damage caused by hypertension
Source: Hypertension News From Medical News Today [2015.09.18]
Researchers have found that a new imaging technique known as diffusion tensor imaging can show when high blood pressure causes early damage to neural pathways in the brain.

Popular hypertension drugs linked to worse heart health in blacks compared to whites
Source: Hypertension News From Medical News Today [2015.09.16]
Drugs commonly used to treat high blood pressure, and prevent heart attacks and strokes, are associated with significantly worse cardiovascular outcomes in hypertensive African Americans compared...

more news >>

Published Studies Related to Tarka (Trandolapril / Verapamil)

Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST). [2005.07]
BACKGROUND: The INternational VErapamil SR-Trandolapril Study (INVEST), a prospective, randomized, antihypertensive trial, found that two different medication regimens produced similar blood pressure (BP) control with equivalent cardiovascular (CV) outcomes (death from any cause, nonfatal myocardial infarction [MI], or nonfatal stroke). HYPOTHESIS: The study was undertaken to investigate whether differences exist by global regions in demographics, treatment, and outcomes in the INVEST trial... CONCLUSIONS: In INVEST, regional differences in medication utilization, BP control, and CV outcomes were identified. These disparities warrant further investigation to define appropriate care for patients with hypertension and stable CAD from an international public health perspective.

The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. [2004.07]
CONCLUSIONS: Our results suggest that FDTV is more effective than trandolapril in reducing proteinuria in normotensive, type 2 diabetic patients. This effect on proteinuria is not related with blood pressure reduction.

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. [2003.12.03]
CONTEXT: Despite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials. OBJECTIVE: To compare mortality and morbidity outcomes in patients with hypertension and CAD treated with a calcium antagonist strategy (CAS) or a non-calcium antagonist strategy (NCAS)... CONCLUSION: The verapamil-trandolapril-based strategy was as clinically effective as the atenolol-hydrochlorothiazide-based strategy in hypertensive CAD patients.

The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. [2003.07]
BACKGROUND: We tested whether the combination of verapamil (V) or amlodipine (A) with trandolapril (T) affected proteinuria differently from T alone in patients with nondiabetic nephropathies... CONCLUSION: In patients with nondiabetic proteinuric nephropathies treated with T, the combination of V or A does not significantly increase its antiproteinuric effect.

Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. [2003.05]
BACKGROUND: There is evidence that diuretics and beta blockers impair glucose tolerance, whereas calcium channel blockers and angiotensin converting enzyme blockers lack this metabolic effect. We compared the effect of a combination therapy with a nondihydropyridine calcium channel blocker plus an angiotensin converting enzyme inhibitor and a beta blocker plus a diuretic on hemoglobin A(1c) (Hb A(1c)) in patients with type 2 diabetes and mild-to- moderate hypertension... CONCLUSIONS: HbA(1c) and other parameters of short- and long-term glycemic control were in a more favorable range after antihypertensive treatment with verapamil SR plus trandolapril as compared with atenolol plus chlorthalidone.

more studies >>

Clinical Trials Related to Tarka (Trandolapril / Verapamil)

Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR) [Completed]
The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome

Tarka« vs. Lotrel« in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM) [Completed]
The primary objective of this study is to determine if trandolapril/verapamil (Tarka«) is superior to amlodipine/benazepril (Lotrel«) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and diabetic nephropathy

Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension [Completed]
This study will investigate antihypertensive activity and safety profile of Tarka in Russian hypertension patients by ambulatory blood pressure measurement (ABPM)

Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka« Fixed Combination in Patients With Essential Hypertension [Completed]
The fixed combination of verapamil SR/trandolapril (Tarka«) is an effective, well-tolerated therapy for the treatment of essential hypertension in those who require more than one agent to achieve optimal blood pressure (BP) control. The endpoint is compliance with Tarka« treatment by number/percentage of patients continued on fixed combination Tarka therapy after six months. This Post Marketing Observational Study will be conducted in a prospective, single-arm, single-country, multicenter format. The investigational sites will be the cardiologists, the doctors of internal medicine and general practicians. Since this will be a Post Marketing Observational Study, Tarka┬« will be prescribed in usual manner in accordance with the terms of the local market authorization with regards to dose, population and indication as well as the local guidelines.

Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL) [Completed]
The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.

more trials >>

Reports of Suspected Tarka (Trandolapril / Verapamil) Side Effects

Renal Failure Acute (11)Bradycardia (11)Hypotension (9)Hyperkalaemia (7)Dyspnoea (6)Asthenia (6)Renal Tubular Disorder (5)Drug Interaction (5)Nausea (5)Agitation (4)more >>


Based on a total of 1 ratings/reviews, Tarka has an overall score of 9. The effectiveness score is 10 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.

Tarka review by 51 year old female patient

Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Mild Side Effects
Treatment Info
Condition / reason:   hypertension
Dosage & duration:   240/40 (dosage frequency: once daily) for the period of been taking for couple of years
Other conditions:   hypothyroidism
Other drugs taken:   synthyroid
Reported Results
Benefits:   very effectively reduced my blood pressure to a good level and has amitianed it for the 2+ years I have been taking it.
Side effects:   My lungs feel heavy at times and that produces a hacking cough. It's not all the time, just occasionally. It hasn't been bothersome enough to ask about changing it to something else yet.
Comments:   I'm taking one pill that contains two different blood pressure medications. It has been very effective in controlling my hypertension.

See all Tarka reviews / ratings >>

Page last updated: 2015-09-29

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015